GlassScriptPhysician profile
Claire E Kenneally
NPI 1952521981
$14,421.98
in general payments reported to CMS, 2019-2025
36 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $61.51 · 2021: $64.10 · 2022: $709 · 2023: $664 · 2024: $464 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,950 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,275 · Food and Beverage: $2,079 · Travel and Lodging: $826 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,950.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,275.00 |
| Food and Beverage | $2,078.75 |
| Travel and Lodging | $826.34 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $6,387.18 | 2024-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $5,523.45 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $295.21 | 2022-2025 | Dupixent |
| Pfizer INC. | $229.25 | 2019-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $207.66 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $202.49 | 2023-2024 | Inspire |
| Amgen INC. | $169.36 | 2019-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $164.29 | 2021-2023 | |
| Abbvie INC. | $97.23 | 2019-2025 | |
| Harmony Biosciences LLC | $96.19 | 2025 | |
| Lilly USA, LLC | $92.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $88.17 | 2019-2023 | Bexsero, Arexvy, Shingrix |
| Hikma Pharmaceuticals USA | $74.86 | 2019-2022 | |
| Sanofi Pasteur INC. | $60.22 | 2019-2020 | |
| Vbi Vaccine (Delaware) INC. | $55.85 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Kenneally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.